
News|Articles|June 1, 2002
The potency/efficacy of the fluoroquinolones in community-acquired pneumonia
This article reviews the efficacy of fluoroquinolones for treating community-acquired pneumonia (CAP) and discusses clinical advantages of fluoroquinolones relative to other drug classes. Of 19 randomized, controlled trials comparing a fluoroquinolone with another agent or combination of agents in CAP, 6 trials have demonstrated superiority of the fluoroquinolone with respect to clinical and/or bacteriologic efficacy.
Advertisement
Advertisement
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Growth of GLP-1 therapies has reshaped the market | PBMI 2026
2
Judi Health, Employers Health team up to launch new PBM solution
3
Deborah Dempsey, Pharm.D., MBA, RPh, on 340B discounts vs. rebates | PBMI 2026
4
Amivantamab, chemo combo shows nearly 3-year survival in EGFR exon 20 lung cancer
5

















